Compagnie Lombard Odier SCmA Acquires 10,720 Shares of Medtronic PLC $MDT

Compagnie Lombard Odier SCmA boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 10.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,850 shares of the medical technology company’s stock after buying an additional 10,720 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Medtronic were worth $10,648,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Corundum Trust Company INC bought a new stake in shares of Medtronic during the third quarter worth about $27,000. Lodestone Wealth Management LLC acquired a new stake in shares of Medtronic in the 4th quarter worth about $27,000. Board of the Pension Protection Fund bought a new position in Medtronic in the 4th quarter valued at about $29,000. GoalVest Advisory LLC bought a new position in Medtronic in the 4th quarter valued at about $29,000. Finally, Valley Wealth Managers Inc. acquired a new position in Medtronic during the 3rd quarter valued at about $29,000. 82.06% of the stock is owned by institutional investors.

Medtronic Trading Down 0.6%

NYSE:MDT opened at $86.13 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market cap of $110.58 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 2.23 and a beta of 0.75. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The firm has a 50-day moving average price of $95.05 and a two-hundred day moving average price of $96.34.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s payout ratio is currently 79.11%.

Wall Street Analyst Weigh In

A number of analysts have commented on MDT shares. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Mizuho upgraded Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. cut their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Needham & Company LLC reiterated a “buy” rating and set a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. Finally, Sanford C. Bernstein increased their price target on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.85.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).